Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
$0.00
$0.00
$0.00
N/A1.323,585 shsN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
+1.4%
$0.01
$0.00
$0.04
N/AN/A115,721 shs29,339 shs
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
$0.01
+10.6%
$0.01
$0.01
$0.15
N/AN/A303,047 shs135,596 shs
LBPSW
4D pharma
$0.00
$0.04
$1.29
N/AN/A20,931 shsN/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
-1.41%0.00%-16.67%-33.33%-22.22%
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
+14.86%-19.05%-39.29%-32.00%-92.09%
LBPSW
4D pharma
0.00%0.00%0.00%0.00%0.00%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
0.00
N/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
0.00
N/AN/AN/A
LBPSW
4D pharma
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
$522KN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/A0.00N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/A
LBPSW
4D pharma
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
20N/AN/ANot Optionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
460N/AN/ANot Optionable
LBPSW
4D pharma
N/AN/AN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

Anthera Pharmaceuticals stock logo

Anthera Pharmaceuticals OTCMKTS:ANTH

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.0071 +0.00 (+1.43%)
As of 02:10 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

4Front Ventures stock logo

4Front Ventures OTCMKTS:FFNTF

$0.0094 +0.00 (+10.59%)
As of 02:58 PM Eastern

4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.

4D pharma NASDAQ:LBPSW

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.